Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

Eligibility Criteria

• * Documented informed consent of the participant and/or legally authorized representative
• * Willingness to be followed for about 14 months
• * Males or females aged ≥ 18 years at the time of informed consent
• * Patients with thyroid carcinoma of follicular origin (papillary, follicular or Hurthle cell)
• * Known positive BRAFV600E mutation (determined on a previous analysis and/or on a representative formalin-fixed paraffin embedded (FFPE) tumor samples or on a biopsy sample)
• * High risk for recurrence according to the American Thyroid Association (ATA) guideline defined as having one or more of the features below:
• * Gross extrathyroidal extension
• * FTC with extensive vascular invasion (\> 4), although less likely to have BRAF mutation
• * PTC with vascular invasion
• * Advanced nodal disease of (any node \>3 cm, \> 4 nodes, or extra-nodal extension)
• * BRAF+TERT promoter mutation
• * Post op thyroglobulin (TG) suggestive of distant metastasis
• * Distant metastatic sites (only for exploratory arm)
• * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
• * Blood pressure (BP) ≤ 140/90 mm Hg at screening with or without antihypertensive medications and no change in antihypertensive medications within 1 week prior to treatment start
• * Creatinine clearance ≥ 50 mL/min according to the Cockcroft and Gault formula
• * Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
• * Hemoglobin ≥ 9.0 g/dL
• * Platelet count ≥ 100 x 109/L
• * Normal blood coagulation function as evidenced by an International Normalized Ratio (INR) ≤ 1.5
• * Bilirubin ≤ 1.5 × upper limit of normal (ULN) except for unconjugated hyperbilirubinemia or Gilbert's syndrome
• * Alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ≤ 3 × ULN (≤ 5 × ULN if subject has liver metastases)
• * Women of childbearing potential must have a negative urine or serum β-HCG pregnancy test within 7 days prior to the administration of the first study treatment
• * Agreement by women of childbearing potential (WOCBP) and males of childbearing potential\* to use an effective\*\* method of birth control\*\* for at least 3 months prior to screening through 1 year of study follow-up.
• * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \> 1 year (women only)
• * Effective birth control defined as hormonal and/or barrier contraception
• * Non-English speaking persons and adults lacking capacity to consent are not excluded from participation
• * Prior RAI treatment
• * Prior anti-BRAF, anti-MEK treatment such as sorafenib, dabrafenib, vemurafenib, encorafenib, binimetinib, cobimetinib, trametinib, d selumitinib and other TKIs like, lenvatinib, sunitinib, axitinib, cabozantenib, vandatinib, pazopanib use
• * Low to intermediate risk differentiated thyroid cancer (DTC) cases (not having the high-risk features as described above)
• * RAI contraindication
• * Undifferentiated or Medullary (MTC) carcinoma of the thyroid
• * Major surgery within 4 weeks prior to the first dose of treatment
• * Subjects having \> 1 + proteinuria on urine dipstick testing will undergo 24 h urine collection for quantitative assessment of proteinuria. Subjects with urine protein ≥ 1 g/24 h will be ineligible
• * Need for locoregional treatment such as surgery, external beam radiation or thermoablation at inclusion
• * External beam radiation, for thyroid cancer, \<4 weeks prior initiation of treatment
• * Gastrointestinal malabsorption or any other condition that in the opinion of the investigator might affect the absorption of the drugs
• * History of congestive heart failure greater or equal to than New York Heart association (NYHA) Class II, unstable angina, myocardial infarction, or stroke within 6 months of the first dose of treatment, or cardiac arrhythmia associated with significant cardiovascular impairment and uncontrolled hypertension
• * Electrocardiogram (ECG) with QT interval (QTc) interval ≥ 480 msec
• * Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 2 months prior to the first dose of treatment and any other active bleeding, coagulopathy or pathologic condition that would confer a high risk of bleeding
• * Active infection requiring systemic therapy
• * Active malignancy (except for DTC, or definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix or bladder) within the past 24 months
• * Any history of or concomitant medical condition that, in the opinion of the investigator, would compromise subject's ability to safely complete the protocol
• * Females who are pregnant or breastfeeding
• * Patients with an injection of radio-contrast agent within 12 weeks prior to enrollment (can be enrolled after 12 weeks)
• * Previous history of retinal vein occlusion
• * Previous history of central serious retinopathy
• * Known hypersensitivity to the study drugs or to any of the excipients
• * Any other condition (including psychosocial condition) that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
• * Any other condition that would confound study results
• * Noncompliance
• * Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)